X-PECT Trial is Fully Enrolled

The X-PECT phase III clinical trial has finished recruiting over 430 patients, evaluating perifosine treatment for patients with advanced colorectal cancer who have exhausted standard treatments. The trial compares the effectiveness of adding perifosine to Xeloda® (capecitabine). Led by Johanna…  Read More

CRC Groups Join Together to Offer Clinical Trial Matching

Leading colorectal cancer advocacy organizations Colon Cancer Alliance and Fight Colorectal Cancer announced that they are teaming up on an initiative to encourage patients with colorectal cancer to take charge of their diagnosis and learn about clinical trials. The Colorectal…  Read More

Hedgehog Fails to Help Advanced Colorectal Cancer Patients

In disappointing news, adding the Hedgehog inhibitor GDC-0449 to standard chemotherapy failed to increase the time before advanced colorectal cancer got worse. Researchers compared progression-free survival between patients who got either FOLFOX or FOLFIRI chemotherapy with Avastin and a group…  Read More

No Benefit Adding Cetuximab to Chemo for Stage III Colon Cancer

Adding Erbitux® (cetuximab) to standard chemotherapy for stage III colon cancer didn’t improve patient outcomes and added more side effects. All of the patients in the NO147 trial had cancer that had spread to their lymph nodes and had surgery…  Read More

Clinical Trial at NIH for Unresectable Liver Tumors

Patients with liver tumors, including those that have spread from colorectal cancer, can enroll in a clinical trial at the National Institutes of Health Clinical Center in Bethesda. The trial will test the effectiveness of infusing the drug melphalan through…  Read More